Shridar Ganesan, MD, PhD,  is a medical oncologist and physician-scientist. He obtained a A.B. in Chemistry from Princeton University  and then received an M.D. and a Ph.D. in Cell Biology at Yale University. He completed residency training in Internal Medicine at the Brigham and Women’s Hospital and where he  also served a year as Chief Medical Resident. He then completed a fellowship in Medical Oncology at the Dana Farber Cancer Institute, and further post-doctoral training in the laboratory of Dr. David Livingston.  He was recruited to Rutgers-CINJ as an  Assistant Professor and established his laboratory focused on DNA repair and cancer genomics where he has been an active physician scientist for the past 17 years. His laboratory has made significant contributions to the understanding of the role of BRCA1 in DNA double-strand break repair,  the maintenance of genetic and epigenetic stability, and the regulation of DNA repair choice. More recently his laboratory has focused on cancer genomics and  understanding mechanisms of sensitivity and resistance to both targeted therapy and immunotherapy of cancer.

His work has been funded by the NCI  for the past 17years, and has led to more than 150 publications.  He serves as an Associate Editor of JCO Precision Oncology, and serves on multiple national and international grant review committees. He is now a Professor of Medicine and Pharmacology, holds the Omar Boraie Chair in Genomic Science, serves as Chief of the Section of Molecular Oncology and Associate Director for Translational Research at RCINJ. He leads the precision oncology effort at the Cancer Institute and co-leads the Investigational Therapeutics and Precision Therapeutics Program.